R01AI183266

Refining Trichomonas vaginalis treatment in women and men - abstract

Trichomonas vaginalis is estimated to be the most common non-viral sexually transmitted infection (STI). It causes considerable and costly perinatal/reproductive morbidity, disproportionately affects persons of color, and can amplify HIV transmission.

After our two trials found multi-dose oral metronidazole (MTZ) to be superior to single-dose 2 g oral MTZ, the Centers for Disease Control and Prevention now recommends multi-dose MTZ as the treatment of choice for T. vaginalis in all women. Since neither trial included men and there is a paucity of data in men, single-dose 2 g oral MTZ stands as the recommended treatment for men.

In both female trials, however, even though multi-dose oral MTZ was found to be superior to single-dose MTZ, multi-dose MTZ still had unacceptably high rates of breakthrough infection (9%-11%). With approximately 2.6 million cases of T. vaginalis per year in the United States, over 280,000 persons/year are estimated to be insufficiently treated with multi-dose oral MTZ.

Thus, there is a critical need to refine T. vaginalis treatment. Single-dose 2 g oral secnidazole (SEC), a next generation 5-nitroimidazole, may be a good option. Our recent trial found that single-dose 2 g oral SEC was superior to placebo in T. vaginalis-infected women.

Oral SEC has multiple benefits compared to multi-dose oral MTZ including a longer half-life and improved tolerability. Single-dose SEC poses less burden on the patient and can treat bacterial vaginosis, a common comorbidity among women with T. vaginalis.

On the other hand, MTZ is far less costly and can be given during pregnancy/lactation. The overall goals of this multi-centered, randomized trial are to examine the effectiveness and cost-effectiveness of oral multi-dose MTZ compared to single-dose oral SEC in both women and men with T. vaginalis.

Aim 1. To examine the optimal treatment for T. vaginalis infection in women and men. This will be done by conducting an open-label, randomized, multi-centered, parallel phase IV clinical trial comparing oral multi-dose MTZ (500 mg BID for 7 days) to single-dose oral 2 g SEC for the treatment of T. vaginalis in women and men. The test-of-cure (TOC) visit will be 4 weeks (± 1 week) after completion of treatment. We hypothesize that T. vaginalis repeat infection rates at TOC will be 1.75 lower in the single-dose 2 g oral SEC arm versus the multi-dose oral MTZ arm.

Aim 2. To compare the cost effectiveness of multi-dose oral MTZ versus single-dose oral SEC for the treatment of T. vaginalis infection. We will compare the direct and indirect costs of treatment using either arm, taking into consideration the reproductive and perinatal outcomes associated with T. vaginalis infection as well as increased risk for HIV-acquisition. We hypothesize the single-dose SEC will have higher initial cost but will be more cost effective compared to multi-dose MTZ, largely due to lower breakthrough rates.

Data from these aims will fill critical gaps in the literature and provide data on refining the treatment of T. vaginalis among women and men, with the long-term goal of reducing health disparities attributable to this common infection.

The Administrators Of Tulane Educational Fund

TO ASSIST PUBLIC AND PRIVATE NONPROFIT INSTITUTIONS AND INDIVIDUALS TO ESTABLISH, EXPAND AND IMPROVE BIOMEDICAL RESEARCH AND RESEARCH TRAINING IN INFECTIOUS DISEASES AND RELATED AREAS, TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS. TO ASSIST PUBLIC, PRIVATE AND COMMERCIAL INSTITUTIONS TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS, TO PROVIDE RESEARCH SERVICES AS REQUIRED BY THE AGENCY FOR PROGRAMS IN INFECTIOUS DISEASES, AND CONTROLLING DISEASE CAUSED BY INFECTIOUS OR PARASITIC AGENTS, ALLERGIC AND IMMUNOLOGIC DISEASES AND RELATED AREAS. PROJECTS RANGE FROM STUDIES OF MICROBIAL PHYSIOLOGY AND ANTIGENIC STRUCTURE TO COLLABORATIVE TRIALS OF EXPERIMENTAL DRUGS AND VACCINES, MECHANISMS OF RESISTANCE TO ANTIBIOTICS AS WELL AS RESEARCH DEALING WITH EPIDEMIOLOGICAL OBSERVATIONS IN HOSPITALIZED PATIENTS OR COMMUNITY POPULATIONS AND PROGRESS IN ALLERGIC AND IMMUNOLOGIC DISEASES. BECAUSE OF THIS DUAL FOCUS, THE PROGRAM ENCOMPASSES BOTH BASIC RESEARCH AND CLINICAL RESEARCH. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM EXPANDS AND IMPROVES PRIVATE SECTOR PARTICIPATION IN BIOMEDICAL RESEARCH. THE SBIR PROGRAM INTENDS TO INCREASE AND FACILITATE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATES AND FOSTERS SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. RESEARCH CAREER DEVELOPMENT AWARDS SUPPORT THE DEVELOPMENT OF SCIENTISTS DURING THE FORMATIVE STAGES OF THEIR CAREERS. INDIVIDUAL NATIONAL RESEARCH SERVICE AWARDS (NRSAS) ARE MADE DIRECTLY TO APPROVE APPLICANTS FOR RESEARCH TRAINING IN SPECIFIED BIOMEDICAL SHORTAGE AREAS. IN ADDITION, INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDS ARE MADE TO ENABLE INSTITUTIONS TO SELECT AND MAKE AWARDS TO INDIVIDUALS TO RECEIVE TRAINING UNDER THE AEGIS OF THEIR INSTITUTIONAL PROGRAM.

93.855 - Allergy and Infectious Diseases Research

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

New Orleans, Louisiana 701185665 United States

Single Zip Code

Research Project Grant (Parent R01 Clinical Trial Required) (PA-20-183)

Amendment Since initial award the total obligations have increased 217% from $1,313,177 to $4,168,595.